Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.,American Journal of Ophthalmology

当前位置： X-MOL 学术 › Am. J. Ophthalmol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.
American Journal of Ophthalmology ( IF 4.1 ) Pub Date : 2022-08-14 , DOI: 10.1016/j.ajo.2022.07.018
Gala Beykin ₁ , Laurel Stell ₁ , Muhammad Sohail Halim ₁ , Mariana Nuñez ₁ , Lilia Popova ₁ , Bac T Nguyen ₁ , Sylvia L Groth ₁ , Amy Dennis ₁ , Zhongqiu Li ₁ , Melissa Atkins ₁ , Tom Khavari ₁ , Sophia Y Wang ₁ , Robert Chang ₁ , Ann C Fisher ₁ , Yasir J Sepah ₁ , Jeffrey L Goldberg ₁

Affiliation

Abstract not available

中文翻译：